Ani pharmaceuticals announces launch of aspirin and extended release dipyridamole capsules, 25mg/200mg
Ani pharmaceuticals, inc. announced the launch of aspirin and extended release dipyridamole capsules, 25mg/200mg (the generic equivalent of aggrenox®). this launch represents ani's fifth generic product introduction in 2019. ani acquired the rights to launch this drug in an acquisition executed in 2018. as part of that acquisition, ani entered into a supply agreement for aspirin and extended release dipyridamole capsules whereby ani receives drug product, packaged in the ani label, starting on october 1, 2019 and ending no later than march 1, 2021. ani estimates that the current annual u.s. market for aspirin and extended release dipyridamole capsules is approximately $80 million, based on iqvia data. there are currently six suppliers of this drug in the u.s. market. aspirin and extended-release dipyridamole capsules are indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.
ANIP Ratings Summary
ANIP Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission